Inhibitor Therapeutics Inc (HPPI) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Inhibitor Therapeutics Inc   (HPPI)


Inhibitor Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Inhibitor Therapeutics Inc's ROI in the second quarter of 2026?
Inhibitor Therapeutics Inc recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -209.83%.

Within the Healthcare sector 191 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4030 to 4033.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -67.78 % -58.1 % -50.43 % -44.99 % -39.81 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 0 1 2 3 4
Return On Investment (TTM) -209.83 % -139.58 % -101.78 % -84.56 % -70.43 %
HPPI's Overall Ranking # 4033 # 4030 # 3556 # 3635 # 3181
Seq. Investment Change TTM -34.39 % -25.9 % -19.99 % -17.17 % -14.69 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -3 -3 -3 -3 -3




Return On Investment HPPI's Ranking
Within: No.
Industry # 78
Sector # 192
Overall # 4033

Return On Investment Statistics
High Average Low
554.86 %
-199.31 %
-633.68 %
(Dec 31 2022)   (Sep 30 2015)







Financial Statements
Inhibitor Therapeutics Inc's II. Quarter Investments $ 0 Millions HPPI's Balance sheet
Inhibitor Therapeutics Inc's II. Quarter Income $ -1 Millions Quarterly HPPI's Income Statement
HPPI's Income by Division See HPPI's Income by Division


HPPI Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 2 5 8 11 -1
Y / Y Investment Growth -65 % -39.82 % -26.67 % - -
Net Income in Millions -3 -3 -3 12 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -189.13 % -66.98 % -36.53 % 107.17 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HPPI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HPPI's Competitors
Subscribers only: Roi for Inhibitor Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for HPPI's Customers

Other Ratios
HPPI's Roa HPPI's Inventory Turnover Ratio HPPI's Growth Rates HPPI's Dividend Statistics
HPPI's Profitability Ratios HPPI's Asset Turnover Ratio HPPI's Dividend Growth
HPPI's Roe HPPI's Valuation Ratios HPPI's Financial Strength Ratios HPPI's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-08-16T02:50:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.